Canaccord analyst William Plovanic raised the firm’s price target on Artivion (AORT) to $51 from $50 and keeps a Buy rating on the shares. The firm said Artivion reported a strong Q3, with a beat fueled by growth in both the aortic stent graft business and On-X. The company raised 2025 guidance to reflect the Q3 momentum and provided some 2026 commentary to level set expectations for investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion price target raised to $53 from $47 at Citizens JMP
- Artivion’s Strong Q3 Performance and Growth Prospects Justify Buy Rating
- Artivion Inc. Reports Strong Q3 2025 Financial Results
- Artivion reports Q3 non-GAAP EPS 16c, consensus 15c
- Artivion raises FY25 revenue view to $439M-$445M from $435M-$443M